Instruction for use: Clostilbegyt

Active substance Clomifene

ATX code G03GB02 Clomifene

Pharmacological group

Estrogens, gestagens; Their homologues and antagonists

Nosological classification (ICD-10)

E22.1 Hyperprolactinaemia

Hyperprolactinemia medication, Hyperprolactinaemia with infertility, Hyperprolactinemia in men, Hyperproduction of prolactin, Idiopathic hyperprolactinemia, Chiari-Frommel Syndrome, Forbes-Albright Syndrome, Tumor galactorrhea, Argonsa del Castillo Syndrome,Forbes-Albright Syndrome

E28.2 Polycystic ovary syndrome

Stein-Levental Syndrome, Polycystic ovary, Polycystic ovary syndrome, Stein-Levental Syndrome, Sclerokrostoznaya disease of the ovaries, Stein-Leventhal syndrome, Polycystic ovary syndrome

E29.1 Testicular function

Leydig cell aplasia, Hypogonadism testicular (primary), Androgen deficiency, Eunuchism, Insufficiency androgenic, Reduced function of the sex glands, Androgen insufficiency, Insufficiency of testosterone, Hypoplasia of the testes, Hypofunction of gonads in men, Insufficiency of androgens in men, Insufficiency of Leydig cells

N46 Male infertility

Azoospermia, Asthenospermia, Infertility, Infertility male, Marriage is infertile, Dispersion, Violations of spermatogenesis, Oligoastenozoospermia III-IV stage, Oligoastenospermia, Oligozoospermia, Oligospermia, Disorders of testicular functions, Spermatogenesis disorders, Inhibition of spermatogenesis, Yang syndrome

N91 Lack of menstruation, meager and rare menstruation

Amenorrhea, Amenorrhea hypogonadotropic, Amenorrhea is prolactin-dependent, Oligomenorrhoea, Shortening of the secretory phase of the menstrual cycle, Menstrual disorders, Menstruation disorders, Prolactin-dependent amenorrhea without galactorrhea

N91.1 Secondary amenorrhea

Amenorrhea due to severe diets, Hypogonadotropic amenorrhea, Disgonadotropic amenorrhea, Postcontraceptive amenorrhea

N97 Female infertility

Female infertility in anovulation, Hyperprolactinemic infertility, Hyperprolactinaemia with infertility, Endocrine infertility, Infertility due to hypothalamic-pituitary dysfunction, Infertility infertility, Infertility, Infertility on the background of hyperprolactinaemia, Functional infertility, Marriage is infertile, Infertility of ovarian genesis, Stimulation of the growth of a single follicle

N97.0 Female infertility associated with lack of ovulation

Anovulation, Stimulation of ovulation, Stimulation of a single dominant follicle, Stimulation of the growth of multiple follicles, Anovulatory dysfunction of the ovaries, Anovulatory cycle, Induction of ovulation in the treatment of infertility, Infringement of an ovulation, Anovulatory infertility, Infertility due to anovulation or inadequate maturation of the follicle, The hormone-dependent pathology of the reproductive system, Anovulation chronic, Anovulatory cycles, Infertility associated with anovulation, Incomplete maturation of the follicle

O92.6 Galactorrhea

Chiari-Frommyl Syndrome, Idiopathic galactorrhea

Composition

Tablets 1 table.

active substance:

Clomifene citrate 50 mg

Auxiliary substances: gelatin - 2 mg; Magnesium stearate - 2 mg; Stearic acid - 2 mg; Talc - 5 mg; Potato starch - 39 mg; Lactose monohydrate - 100 mg

pharmachologic effect

The pharmacological action is antiestrogenic.

Dosing and Administration

Inside.

Infertility dose and duration of treatment depend on the sensitivity (response to the drug) of the ovaries. Patients with a regular menstrual cycle are advised to begin treatment from the 5th day of the cycle (or on the 3rd day of the cycle with early ovulation or the duration of the follicular phase is less than 12 days). With amenorrhea, treatment can be started any day.

Scheme I. At 50 mg per day for 5 days with simultaneous control of ovarian response with clinical and laboratory studies. Usually ovulation occurs between the 11th and 15th day of the cycle. If such treatment does not lead to ovulation, scheme II should be applied.

Scheme II. From the 5th day of the next cycle, 100 mg per day for 5 days. If at this time ovulation is not observed, you should repeat the same scheme again (100 mg per day). In case of failure, taking the drug should be interrupted for 3 months, and then repeated treatment within 3 months. If the second course is ineffective, subsequent drug treatment is ineffective. The total amount of the drug taken during each course should not exceed 750 mg.

In polycystic ovaries, due to the tendency to hyperstimulation, treatment should be started with a dose of 50 mg per day.

In the absence of menstruation due to prolonged use of contraceptives should be administered at 50 mg per day, a 5-day course of treatment is usually effective at the first attempt.

Men are prescribed 50 mg 1-2 times a day for 6 weeks (systematic control of the spermogram is necessary).

Form of issue

Tablets, 50 mg. For 10 tab. In a bottle of brown glass with a PE-cap with the control of the first opening and a shock absorber. 1 fl. In a cardboard box. For 10 tab. In a blister of PVC (polyvinyl chloride) / PVDC (polyvinylidene chloride) / aluminum foil. 1 blister in a cardboard box.

Terms of leave from pharmacies

On prescription.

storage Conditions

At a temperature of 15-25 ° C.

Keep out of the reach of children.

Shelf life

5 years.

Do not use after the expiry date printed on the package.